(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
13 May 2004 (13.05.2004)

PCT

(10) International Publication Number
WO 2004/039367 A1

(51) International Patent Classification[7]: A61K 31/401, C07D 207/16, 401/12, A61P 25/00

(21) International Application Number: PCT/IB2003/004697

(22) International Filing Date: 22 October 2003 (22.10.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0225379.7 31 October 2002 (31.10.2002) GB

(71) Applicant *(for GB only)*: **PFIZER LIMITED** [GB/GB]; Ramsgate Road, Sandwich, Kent CT13 9NJ (GN).

(71) Applicant *(for all designated States except GB, US)*: **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, NY 10017 (US).

(72) Inventor; and

(75) Inventor/Applicant *(for US only)*: **RAWSON, David, James** [GB/GB]; Pfizer Global Research and Development, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).

(74) Agents: **STUART, P., Graham** et al.; Pfizer Limited, Ramsgate Road, Kent, CT13 9NJ (GB).


(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PROLINE DERIVATIVES HAVING AFFINITY FOR THE CALCIUM CHANNEL ALPHA-2-DELTA SUBUNIT



(I)

(57) Abstract: The compounds of formula (I) or a pharmaceutically acceptable salt, solvate or pro-drug thereof, are proline derivatives useful in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, fibromyalgia, arthritis, neuropathalogical disorders, sleep disorders, visceral pain disorders and gastrointestinal disorders. Processes for the preparation of the final products and intermediates useful in the process are included. Pharmaceutical compositions containing one or more of the compounds are also included. Wherein either X is O, S, NH or CH2 and Y is CH2 or a direct bond, or Y is O, S or NH and X is CH2; and R is a 3-12 membered cycloalkyl, 4-12 membered heterocycloalkyl, heteroaryl or aryl, where any ring may be optionally substituted with one or more substituents independently selected from halogen, hydroxy, cyano, nitro, amino, hydroxycarbonyl, Cl-C6 alkyl, Cl-C6 alkenyl, CI-C6 alkynyl, C_1-C_6 alkoxy, hydroxyC,-C_6 alkyl, C_1-C_6 alkoxyC,-C_6 alkyl, perfluoro C_1-C_6 alkyl, perfluoroC,-C_6 alkoxy, C_1-C_6 alkylamino, di- C_1-C_6 alkylamino, aminoC_1-C_6 alkyl, C_1-C_6 alkylaminoC,-C_6 alkyl, di-Cl-C6 alkylaminoC,-C6 alkyl, CI-C6acyl, C_1-C_6acyloxy, C_1-C_6acyloxyC,-C_6 alkyl, C_1-C_6 acylamino, C_1-C_6 alkylthio, C_1-C_6 alkylthiocarbonyl, C_1-C_6 alkylthioxo, C_1-C_6 alkoxycarbonyl, C_1-C_6 alkylsulfonyl, C_1-C_6 alkylsulfonylamino, aminosulfonyl, C_1-C_6 alkylaminosulfonyl, di-C_1-C_6 alkylaminosulfonyl, 3-8 membered cycloalkyl, 4-8 membered heterocycloalkyl, phenyl and monocyclic heteroaryl; or a pharmaceutically acceptable salt, solvate or pro-drug thereof.

WO 2004/039367 A1